Welcome to our dedicated page for MapLight Therapeutics SEC filings (Ticker: MPLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics General Counsel Kristopher Hanson reported a tax-related share withholding tied to restricted stock units. On January 27, 2026, the issuer withheld 26,007 shares of Voting Common Stock at $17.98 per share to cover tax obligations from RSU settlement.
After this transaction, Hanson beneficially owned 183,852 shares directly. The remaining securities he holds are still subject to a 180-day IPO lock-up following the final prospectus dated October 26, 2025, limiting his ability to sell or transfer those shares during that period.
MPLT insider Robert Malenka has filed a notice of proposed sale of 21,262 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of 394,469.63 as of the filing.
The shares were acquired on 01/23/2026 through the vesting of restricted stock under a registered plan in exchange for services rendered. The notice also reports a prior sale of 6,524 common shares on 01/28/2026 for gross proceeds of 121,689.56. Shares outstanding were 45,373,033 as of the figures shown; this is a baseline figure, not the amount being sold.
MPLT filed a notice that a shareholder plans to sell restricted stock under Rule 144. The planned sale covers 6,524 shares of common stock, with an aggregate market value of 121,689.56, through Morgan Stanley Smith Barney LLC on or about 01/28/2026 on NASDAQ.
These shares were acquired on 01/23/2026 as restricted stock vesting under a registered plan in exchange for services rendered. The filing notes that, by signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
MapLight Therapeutics disclosed selected preliminary financial information and a development update. For the fiscal year ended December 31, 2025, the company estimates that its cash and cash equivalents were approximately $450 million as of December 31, 2025. This figure is preliminary, unaudited, and may change after completion of year-end closing procedures and the audit of its financial statements.
The company also announced a change in timing for topline data from its ongoing Phase 2 ZEPHYR and IRIS clinical trials, which are now expected in the third quarter of 2026. The cash figure and program updates were included in an updated corporate presentation and a press release furnished as exhibits and made available for investor meetings and on the company’s website.